检索结果-南通市图书馆

Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model

引用

Cellular & Molecular Immunology 2021年第7期18卷 1652-1661页

作者： Jaya Lakshmi Thangaraj Seo-Yeon Ahn Sung-Hoon Jung Manh-Cuong Vo Tan-Huy Chu Minh-Trang Thi Phan Minsuk Kwon Kyung-Hwa Lee Mihee Kim Ga-Young Song deok-hwan yang Jae-Sook Ahn Hyeoung-Joon Kim Duck Cho Je-Jung Lee Research Center for Cancer Immunotherapy Chonnam National University Hwasun Hospital and Chonnam National University Medical SchoolGwangjuKorea Department of Hematology-Oncology Chonnam National University Hwasun Hospital and Chonnam National University Medical SchoolGwangjuKorea Department of Molecular Medicine Chonnam National UniversityGwangjuKorea Stem Cell&Regenerative Medicine Institute Samsung Medical CenterSeoulKorea View author publications Division of Hematology-Oncology Department of MedicineSamsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea Department of Pathology Chonnam National University Medical SchoolGwangjuKorea Department of Health Sciences and Technology SAIHSTSungkyunkwan UniversitySeoulKorea Department of Laboratory Medicine and Genetics Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea

The use of natural killer(NK)cells is a promising and safe immunotherapeutic approach in the field of cancer ***,combination treatments are required to enhance the effector functions and therapeutic efficacy of NK *** this study,we investigated the potential of daratumumab(Dara),bortezomib,and dexamethasone(Dvd)to augment the antitumor effects of NK cells in a multiple myeloma(MM)xenograft mouse *** cells were expanded and activated using the K562-OX40 ligand and membrane-bound IL-18 and IL-21 in the presence of IL-2 and IL-15 from peripheral blood mononuclear cells from MM patients.A human MM xenograft model was established using human RPMI8226-RFP-FLuc cells in NOD/SCID IL-2Rγnull(NSG)***-bearing mice were divided into six treatment groups:no treatment,expanded NK cells(eNKs),Dara,Dara+eNKs,Dvd,and Dvd+*** treatment strongly enhanced the cytotoxicity of eNKs by upregulating expression of NK cell activation ligands,downregulating expression of NK cell inhibitory ligands,and promoting antibody-dependent cellular *** combination of eNKs with Dvd significantly prolonged mouse survival and reduced the tumor burden and serum M-protein ***,Dvd pretreatment significantly increased eNK persistence and homing to MM *** findings suggest that Dvd treatment potentiates the antimyeloma effects of NK cells expanded and activated ex vivo by modulating immune responses in MM-bearing mice.

关键词： Multiple myeloma Natural killer cell Chemotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists

引用

Cellular & Molecular Immunology 2011年第4期8卷 341-347页

作者： Thanh-Nhan Nguyen-Pham Mi-Seon Lim Truc Anh Thi Nguyen Youn-Kyung Lee Chun-Ji Jin Hyun Ju Lee Cheol Yi Hong Jae-Sook Ahn deok-hwan yang Yeo-Kyeoung Kim Ik-Joo Chung Byoung Chul Park Hyeoung-Joon Kim Je-Jung Lee Research Center for Cancer Immunotherapy Chonnam National University Hwasun HospitalJeollanamdoKorea Department of Hematology-Oncology Chonnam National UniversityGwangjuKorea The Brain Korea 21 Project Center for Biomedical Human Resources at Chonnam National UniversityGwangjuKorea Vaxcell-Bio Therapeutics JeollanamdoKorea Korea Research Institute of Bioscience and Biotechnology(KRIBB) DaejeonKorea

The major limitation for the maturation of dendritic cells(DCs)using Toll-like receptor(TLR)agonists is their decreased ability to migrate into lymph nodes compared with conventional ***38 can be used as a multifunctional marker to modulate migration,survival and Th1 responses of ***74 has been shown to negatively regulate DC *** goal of this study was to investigate the combinations of TLR agonists and interferons(IFNs)that most effectively regulate CD38 and CD74 expression on *** TLR agonist stimulation in combination with IFN-a and IFN-c was the best method for regulating CD38 and CD74 expression and inducing the highest secretion of *** in vitro migration assay showed that DCs treated with this combination had significantly enhanced migratory ability,similar to that observed in cells expressing CD38,CD74 and *** results of this study suggest that an alternative maturation protocol in which two TLR ligands are combined with type I and II IFNs generates potent DCs that have both a high migratory capacity and high IL-12p70 production.

关键词： CD38 CD74 dendritic cells interferon Toll-like receptor

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy

引用

Cellular & Molecular Immunology 2012年第1期9卷 45-53页

作者： Thanh-Nhan Nguyen-Pham deok-hwan yang Truc-Anh Thi Nguyen Mi-Seon Lim Cheol Yi Hong Mi-Hyun Kim Hyun Ju Lee Youn-Kyung Lee Duck Cho Soo-Young Bae Jae-Sook Ahn Yeo-Kyeoung Kim Ik-Joo Chung Hyeoung-Joon Kim Je-Jung Lee Research Center for Cancer Immunotherapy Chonnam National University Hwasun HospitalJeollanamdoKorea Department of Hematology-Oncology Chonnam National University Hwasun HospitalJeollanamdoKorea Vaxcell-Bio Therapeutics JeollanamdoKorea The Brain Korea 21 Project Center for Biomedical Human Resources at Chonnam National UniversityGwangjuKorea

Dendritic cell(DC)-based vaccines continue to be considered an attractive tool for cancer *** require an additional signal from the environment or other immune cells to polarize the development of immune responses toward T helper 1(Th1)or Th2 *** play a role in natural killer(NK)cell activation,and NK cells are also able to activate and induce the maturation of *** investigated the types of NK cells that can induce the maturation and enhanced function of DCs and the conditions under which these interactions *** that were activated by resting NK cells in the presence of inflammatory cytokines exhibited increased expression of several costimulatory molecules and an enhanced ability to produce *** cell-stimulated DCs potently induced Th1 polarization and exhibited the ability to generate tumor antigen-specific cytotoxic T lymphocyte *** data demonstrate that functional DCs can be generated by coculturing immature DCs with freshly isolated resting NK cells in the presence of Toll-like receptor agonists and proinflammatory cytokines and that the resulting DCs effectively present antigens to induce tumor-specific T-cell responses,which suggests that these cells may be useful for cancer immunotherapy.

关键词： cancer immunotherapy dendritic cells natural killer cells signal

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy

引用

Cellular & Molecular Immunology 2021年第6期18卷 1599-1601页

作者： Manh-Cuong Vo Seo-Yeon Ahn Tan-Huy Chu Saji Uthaman Shammer Pillarisetti Tung Nguyen Thanh Uong Thangaraj Jaya Lakshmi Mihee Kim Ga-Young Song Sung-Hoon Jung deok-hwan yang Jae-Sook Ahn Hyeoung-Joon Kim In-Kyu Park Je-Jung Lee Institute of Research and Development Duy Tan UniversityDanangVietnam Research Center for Cancer Immunotherapy Chonnam National University Hwasun HospitalHwasunJeollanamdoRepublic of Korea Department of Hematology-Oncology Chonnam National University Hwasun HospitalChonnam National University Medical SchoolGwangjuRepublic of Korea Department of Polymer Science and Engineering Chungnam National UniversityDaejeonRepublic of Korea Department of Biomedical Science Chonnam National University Medical SchoolGwangjuRepublic of Korea Department of Radiation Oncology Chonnam National University Hwasun HospitalChonnam National University Medical SchoolGwangjuSouth Korea View author publications

Nanovaccines are used as delivery platforms for antigens and adjuvants, which activate antigen-presenting cells (APCs) and enhance anticancer immune responses.1,2 Researchers have recently developed a self-assembled nanocomplex using a polysorbitol-co-PEI (PSPEI) polymer complexed with poly(I:C) (PIC). By binding to different surface proteins, this nanocomplex enhances the intracellular delivery of cargos and induces potent anticancer immune responses against melanoma cells.3 We have previously demonstrated that PD-1/PD-L1 blockade enhanced the efficacy of DC-based cancer immunotherapy.4,5 Moreover, the combination of nanomedicines and PD-L1 blockade has been reported to enhance CD8+ T cell activation and inhibit immunosuppressive cells within the tumor microenvironment.6 In the present study, we investigated the therapeutic efficacy of a combinatorial treatment comprising the immunoadjuvant nanocomplex PSPEI-PIC, a DC vaccine, and PD-L1 blockade in a murine colon cancer model.

关键词： adjuvant vaccines immunotherapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma:amulticenter,retrospective analysis

引用

Cancer Communications 2021年第3期41卷 275-278页

作者： Jun Ho Yi Seok Jin Kim Dok Hyun Yoon Cheolwon Suh Myung Hee Chang deok hwan yang Jae-Cheol Jo Shin Young Hyun Hyeon-Seok Eom Jeong-Ok Lee Ji Hyun Kwon Sang Hoon Han Seung-Shin Lee Jae-Yong Kwak Se Hyung Kim Dae Sik Kim Ji Hyun Lee Sung Yong Oh Hun Mo Ryoo Hyo Jung Kim Won Seog Kim Division of Hematology-Oncology Department of MedicineChung-Ang UniversityDongjak-guSeoul 06973Korea Division of Hematology and Oncology Department of MedicineSamsung Medical Center Sungkyunkwan University School of MedicineGangnam-guSeoul 06351Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guSeoul 05505Korea National Health Insurance Corporation Ilsan Hospital Ilsandong-guGoyang 10444Korea Department of Hemato-Oncology Chonnam National University Hwasun HospitalChonnam National University Medical SchoolHwasunGwangju 58128Korea Department of Hematology and Oncology Ulsan University HospitalUniversity of Ulsan College of MedicineDong-guUlsan 44033Korea Department of Internal Medicine Yonsei University Wonju College of MedicineGangwon-DoWonju 26426Korea Department of Internal Medicine National Cancer CenterGoyang-si Gyeonggi-doGoyang 10408Korea Department of Internal Medicine Seoul National University Bundang HospitalBundang-guSeongnam 13620Korea Department of Internal Medicine ChungBuk National University HospitalChungbukCheongju 28644Korea Department of Internal Medicine Jeju National University HospitalJeju National University School of MedicineJeju 63241Korea Department of Hematology-Oncology Wonkwang University HospitalIksan-daeroIksan 54538Korea Department of Internal Medicine Jeonbuk National University Medical SchoolJeollabuk-doJeonju 54907Korea Division of Hematology-Oncology Department of Internal MedicineSoonchunhyang University College of MedicineBucheon HospitalWonmi-guBucheon 14584Korea Division of Hematology-Oncology Department of Internal MedicineKorea University Guro HospitalGuro-guSeoul 08308Korea Division of Hematology-Oncology Department of Internal MedicineDong-A University College of MedicineSeo-guBusan 49201Korea Department of Internal Medicine Division of Hematology-Oncology Catholic University of DaeguDaegu 42472Korea Division of Hematology-Oncology Department of Internal MedicineHallym U

Dear Editor,Despite the introduction of novel front-line therapies including rituximab plus high-dose cytarabine followed by consolidative autologous stem cell transplantation(ASCT)and salvage therapy with bendamustine,lenalidomide or bortezomib,mantle cell lymphoma(MCL)is still considered incurable and most patients experience relapse or refractory(RR)disease.

关键词： patients relapse lymphoma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A Multi-Center International Survey Related to the Nutritional Support after Hematopoietic Stem Cell Transplantation Endorsed by the ASIA Pacific Blood and Marrow Transplantation (APBMT)

引用

Food and Nutrition Sciences 2012年第3期3卷 417-421页

作者： Shigeo Fuji Takehiko Mori Vincent Lee Jessica Cheng Natalie Linton Albert Lie Navin Khattry Akio Shigematsu Naoyuki Uchida Tetsuya Eto Nguyen Duy Thang Yi-Chang Liu deok-hwan yang Jin Seok Kim Joon Ho Moon Dae-Young Kim Minako Iida Ritsuro Suzuki Yoshihisa Kodera Sung-Won Kim Department of Hematology and Hematopoietic Stem Cell Transplantation National Cancer Center Hospital Tokyo Japan. Department of Hematology and Oncology Chonnam National University Hwasun Hospital Jeollanam-do Korea Department of Hematology and Oncology Hokkaido University Hospital Hokkaido Japan Department of Hematology and Oncology Kaohsiung Medical University Hospital Taiwan (China) Department of Hematology and Oncology Kyungpook National University Hospital Daegu Korea (South) Department of Hematology Asan Medical Center Seoul Korea (South) Department of Hematology Hamanomachi Hospital Fukuoka Japan Department of Hematology Toranomon Hospital Tokyo Japan Department of Hematology University Hospital Wuerzburg Wuerzburg Germany Department of HSCT Data Management and Biostatistics School of Medicine Nagoya University Nagoya Japan Department of Medical Oncology Tata Memorial Center Mumbai India Department of Medicine Queen Mary Hospital Hong Kong (China) Department of Nutrion Services St Vincent’s Hospital Sydney Sydney Australia Department of Pediatrics The Chinese University of Hong Kong Prince of Wales Hospital Hong Kong (China) Department of Promotion for Blood and Marrow Transplantation School of Medicine Aichi Medical University Nagakute Japan Division of Hematology Keio University Hos- pital Tokyo Japan Division of Hematology Yonsei University College of Medicine Severance Hospital Seoul Korea (South) Hue Regional Hematology and Blood Transfusion Center Hue Central Hospital Hue City Vietnam

Background: The nutritional support after hematopoietic stem cell transplantation (HSCT) has not been well established due to the scarcity of clinical trials. To conduct international clinical trials in Asia, we performed the questionnaire survey to investigate the current standard of nutritional support after HSCT. Method: We sent the questionnaire to the physicians nominated by the Asia Pacific Blood and Marrow Transplantation (APBMT) members of each country/ region. Result: We received 15 responses from 7 different countries/regions. The target calorie amount is 1.0 - 1.3 × basal energy expenditure (BEE) in 11 institutes when partial parenteral nutrition is used. When total parenteral nutrition (TPN) is used, the target calorie amount is 1.0 - 1.3 × BEE in 9 institutes and 1.3 - 1.5 × BEE in 4 institutes. Lipid emulsion is routinely used in 12 institutes. Multivitamins and trace elements are routinely added to TPN used in most institutes. It is still uncommon to use the immunonutrition. Blood glucose levels are routinely monitored in all institutes, but the target range varies (<110 in 2 institutes, <150 in 4 institutes, and <200 in 8 institutes). Conclusions: Basic nutritional support is similar in participating institutes. However, the target glucose level varies and the use of immunonutrition is rather rare. These points can be the theme of future clinical trials.

关键词： Stem Cell Transplantation Nutritional Support Asia Pacific Blood and Marrow Transplantation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A hybrid storage technology for low power consumption and high I/O performance in an IPTV set-top box

引用

Journal of Central South University 2012年第5期19卷 1267-1275页

作者： KIM deok-hwan yang Jun-sik Department of Electronics Engineering Inha UniversityIncheon 402-751Korea

A new method of prefetching data blocks from the NVCache to the page cache in main memory and cascading prefetching n-blocks from a hard disk to the NVCache together was proposed to reduce the spin-up frequency of a hybrid hard disk drive and thus enhance I/O *** proposed method consists of three steps:1) Analyzing the pattern of read requests in block units;2) Determining the number of blocks prefetched to the NVCache;3) Replacing blocks in the NVCache according to the block replacement *** proposed method can reduce the latency time of a hybrid hard disk and optimize the power consumption of an IPTV set-top *** results show that the proposed method provides better average response time compared to an existing adaptive multistream prefetching(AMP) method by 25.17%.It also reduces by 20.83% the average power consumption over that of the existing external caching in energy saving storage system(EXCES) method.

关键词： IPTV set-top box hybrid hard disk prefetching spin-down low power consumption

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Phase Ⅱ study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma:consortium for improving survival of lymphoma(CISL)study

引用

Cancer Communications 2019年第1期39卷 526-535页

作者： Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Dok Hyun Yoon deok-hwan yang Won Sik Lee Hyo Jung Kim Ho-Young Yhim Seong Hyun Jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung-Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong-Won Lee Jae Hoon Lee Ho Sup Lee Ho-Jin Shin Cheolwon Suh Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea Division of Hematology Department of Internal MedicineYonsei University College of MedicineSeoul 03722Republic of Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guSeoul 05505Republic of Korea Department of Hematology-Oncology Chonnam National University Hwasun HospitalHwasun 58128Republic of Korea Department of Hematology Busan Paik HospitalInje University College of MedicineBusan 04511Republic of Korea Department of Internal Medicine Hallym University Sacred Heart HospitalHallym University College of MedicineAnyang 14068Republic of Korea Department of Internal Medicine Chonbuk National University HospitalJeonju 54907Republic of Korea Department of Hematology-Oncology Ajou University School of MedicineSuwon 16499Republic of Korea Department of Internal Medicine Soonchunhyang University Seoul HospitalSoonchunhyang University College of MedicineSeoul 04401Republic of Korea Division of Hematology-Oncology Department of Internal MedicineWonju Severance Christian HospitalYonsei University College of MedicineWonju 26426Republic of Korea Department of Internal Medicine Haeundae Paik HospitalInje University College of MedicineBusan 48108Republic of Korea Division of Hematology and Oncology Department of Internal MedicineSamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Republic of Korea Division of Hematology-Oncology Department of Internal MedicineDongnam Institute of Radiological and Medical SciencesBusan 46033Republic of Korea Division of Hematology-Oncology Department of Internal MedicineGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Republic of Korea Department of Internal Medicine Gachon University Gil Medical CenterIncheon 21565Republic of

Background:The response rate and survival improvement for rituximab,a CD20-targeting monoclonal antibody,have been demonstrated in marginal zone lymphoma(MZL)as monotherapy and in combination with chemotherapeutic regimens,yet relapses still occur despite treatment ***,extending the period of remission in MZL patients remains an essential *** multicenter,single-arm,open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone).The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further ***:Prior to rituximab-maintenance therapy,patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV ***(375 mg/m^(2)),cyclophosphamide(750 mg/m^(2)),and vincristine(1.4 mg/m^(2);maximum 2 mg)were administered via an intravenous infusion on day 1 of each 3-week cycle,while oral prednisolone(100 mg)was given on days 1-5 of each 3-week *** patients who achieved complete response(CR),partial response(PR),or stable disease(SD)to R-CVP treatment,were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m^(2) every 8 weeks for up to 12 *** primary endpoint was progression-free survival(PFS).Secondary endpoints were overall survival(OS)and treatment ***:47 patients were enrolled,of whom,45(96%)received rituximab-maintenance ***(33%)patients had nodal *** R-CVP first-line therapy,20(44%),22(49%),and 3(7%)patients achieved CR,PR,and SD,*** a median follow-up of 38.2 months,their observed 3-year PFS rate was 81%.During the rituximab-maintenance,6 PR and 1 SD patients achieved CR following the administration of *** LDH and the presence of B symptoms were found to be significant prognostic fac

关键词： Marginal zone Lymphoma Advanced stage Rituximab Cyclophosphamide Vincristine Maintenance Multicenter Open label Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

边缘区淋巴瘤晚期患者R-CVP后利妥昔单抗维持治疗的Ⅱ期研究:一项改善淋巴瘤生存协会(CISL)的研究

引用

癌症 2020年第3期39卷 118-128页

作者： Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Dok Hyun Yoon deok‑hwan yang Won Sik Lee Hyo Jung Kim Ho‑Young Yhim Seong Hyun Jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung‑Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong‑Won Lee Jae Hoon Lee Ho Sup Lee Ho‑Jin Shin Cheolwon Suh Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea Division of Hematology Department of Internal MedicineYonsei University College of MedicineSeoul 03722Republic of Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa‑guSeoul 05505Republic of Korea Department of Hematology‑Oncology Chonnam National University Hwasun HospitalHwasun 58128Republic of Korea Department of Hematology Busan Paik HospitalInje University College of MedicineBusan 04511Republic of Korea Department of Internal Medicine Hallym University Sacred Heart HospitalHallym University College of MedicineAnyang 14068Republic of Korea Department of Internal Medicine Chonbuk National University HospitalJeonju 54907Republic of Korea Department of Hematology‑Oncology Ajou University School of MedicineSuwon 16499Republic of Korea Department of Internal Medicine Soonchunhyang University Seoul HospitalSoonchunhyang University College of MedicineSeoul 04401Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineWonju Severance Christian HospitalYonsei University College of MedicineWonju 26426Republic of Korea Department of Internal Medicine Haeundae Paik HospitalInje University College of MedicineBusan 48108Republic of Korea Division of Hematology and Oncology Department of Internal MedicineSamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineDongnam Institute of Radiological and Medical SciencesBusan 46033Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Republic of Korea Department of Internal Medicine Gachon University Gil Medical CenterIncheon 21565Republic of

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多... 详细信息

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多中心、单臂、开放标签的Ⅱ期研究评估了对一线R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone;利妥昔单抗、环磷酰胺、长春新碱和泼尼松龙)治疗有反应的Ⅲ–Ⅳ期CD20阳性MZL患者进行利妥昔单抗维持治疗2年的生存率。本研究旨在明确R-CVP后利妥昔单抗维持治疗的策略是否有进一步研究的价值。方法在利妥昔单抗维持治疗之前,Ⅲ–Ⅳ期MZL患者应接受6–8周期的R-CVP一线治疗。每个周期为3周,第1 d静脉输注利妥昔单抗(375 mg/m^2)、环磷酰胺(750 mg/m^2)和长春新碱(1.4 mg/m^2;最大2 mg),第1–5 d口服泼尼松龙(100 mg)。对R-CVP治疗达到完全缓解(complete response,CR)、部分缓解(part response,PR)或疾病稳定(stable response,SD)的患者进行利妥昔单抗维持治疗,每8周静脉注射利妥昔单抗375mg/m^2,直到12个周期。主要终点为无进展生存期(progression-free surviva,PFS),次要终点为总生存期(overall survival,OS)和治疗安全性。结果共纳入47例患者,其中45(96%)例接受了利妥昔单抗维持治疗。15(33%)例患者有淋巴结MZL。在进行R-CVP一线治疗后,分别有20(44%)例、22(49%)例和3(7%)例的患者达到了CR、PR和SD。中位随访38.2个月后,患者的3年PFS率为81%。在利妥昔单抗维持治疗期间,R-CVP治疗后有6例PR和1例SD患者获得CR。LDH升高和B症状是PFS的重要预后因素(P=0.003),3年OS率为90%。利妥昔单抗维持治疗的耐受性良好,常见的治疗性不良事件为感觉性神经病(18%)、肌痛(13%)、疲劳(9%)和中性粒细胞减少(9%)。结论一线R-CVP治疗后利妥昔单抗维持治疗在Ⅲ–Ⅳ期MZL患者中不仅表现出较好的PFS,而且药物毒性反应评价良好。

关键词：边缘区淋巴瘤晚期利妥昔单抗环磷酰胺长春新碱维持多中心开放标签生存

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Predictability of the East Asian Winter Monsoon Indices by the Coupled Models of ENSEMBLES

引用

Advances in Atmospheric Sciences 2014年第6期31卷 1279-1292页

作者： Se-hwan yang LU Riyu State Key Laboratory of Numerical Modelling for Atmospheric Sciences and Geophysical Fluid Dynamics Institute of Atmospheric Physics Chinese Academy of Sciences University of Chinese Academy of Sciences

The seasonal predictability of various East Asian winter monsoon （EAWM） indices was investigated in this study based on the retrospective forecasts of the five state-of-the-art coupled models from ENSEMBLES for a 46-year period of *** was found that the ENSEMBLES models predict five out of the 21 EAWM indices well,with temporal correlation coefficients ranging from 0.54 to *** five indices are defined by the averaged lower-tropospheric winds over the low latitudes （south of 30°N）.Further analyses indicated that the predictability of these five indices originates from their intimate relationship with ENSO.A cross-validated prediction,which took the preceding （November） observed Nifo3.4 index as a predictor,gives a prediction skill almost identical to that shown by the *** the other hand,the models present rather low predictability for the other indices and for surface air temperature in East *** addition,the models fail to reproduce the relationship between the indices of different categories,implying that they cannot capture the tropicalextratropical interaction related to EAWM ***,these results suggest that reliable prediction of the EAWM indices and East Asian air temperature remains a challenge.

关键词： East Asian winter monsoon dynamical index predictability ENSO ENSEMBLES

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：